Tetrakis(vinylsulfonylmethyl)methane | 60345-53-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: Tetrakis(vinylsulfonylmethyl)methane
• 英文别名: 1,3-bis(ethenylsulfonyl)-2,2-bis(ethenylsulfonylmethyl)propane
• CAS: 60345-53-1
• 化学式: C₁₃H₂₀O₈S₄
• 分子量: 432.6
• InChiKey: CFSGUMFOSQULCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  25
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  170
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  磷酸 、 双氧水 、 Tetrakis(2-chloroethylsulfonylmethyl)methane 在 丙酮 、 盐酸 、 Acetone ethanol 作用下， 生成 Tetrakis(vinylsulfonylmethyl)methane
  参考文献：
  名称：

  Silver halide photographic element containing a gelatinous layer

  摘要：

  一种摄影元素，包括一个支撑层和涂覆在其上的含明胶层，其中该明胶层包含已经用具有分子结构中的脂肪烃链至少有3个乙烯磺酰基键合的化合物硬化的明胶。

  公开号：

  US04088495A1

文献信息

• Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：US20030065175A1

  公开（公告）日：2003-04-03

  The present invention relates to novel oxazolidinone compounds of the general formula (I) 1 where R 1 , R 2 , R 3 , Y 1 , Y 2 , Y 3 , and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutical acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

  本发明涉及一种新型噁唑啉化合物，其通式为（I）1，其中R1、R2、R3、Y1、Y2、Y3和Z如描述中所定义；它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂化合物以及含有它们的制药组合物。
• Novel heterocyclic compounds having antibacterial activity: Process for their preparation and pharmaceutical compositions containing them
  申请人：DR. REDDY'S LABORATORIES INC.

  公开号：US20040059120A1

  公开（公告）日：2004-03-25

  The present invention relates to novel oxazolidinone compounds of the general formula (I). 1 where R 1 , R 2 , R 3 , Y 1 , Y 2 , Y 3 , and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

  本发明涉及一种新的氧唑啉化合物，其一般式为（I）1，其中R1，R2，R3，Y1，Y2，Y3和Z如描述中所定义；它们的衍生物，类似物，互变异构体，立体异构体，多晶形，药学上可接受的盐，药学上可接受的溶剂和包含它们的药物组合物。
• Security laminates with interlaminated transparent embossed polymer hologram
  申请人：AGFA-GEVAERT

  公开号：EP2042577A1

  公开（公告）日：2009-04-01

  A method for interlaminating a transparent embossed hologram, said transparent embossed hologram comprising an optionally transparent support having two sides, at least one of the two sides either itself being embossed or having a layer thereon which is embossed and a layer of an inorganic HRI-material applied by a vacuum technique contiguous with said embossed side or embossed layer, comprising the steps of: coating the outermost surface of said layer of HRI-material with an aqueous solution or dispersion of at least one polyhydroxy polymer; drying said coating thereby forming a transparent continuous laminatable layer 2; and laminating said transparent continuous laminatable layer 2 to an optionally transparent foil, wherein at least one of said support and said foil is transparent; a laminate comprising an interlaminated transparent embossed hologram, said transparent embossed hologram comprising an optionally transparent support having two sides, at least one of the two sides either itself being embossed or having a layer thereon which is embossed and a layer of a HRI-material applied by a vacuum technique contiguous with said embossed side or embossed layer having an adhesive layer between said layer of HRI-material and an optionally transparent foil, wherein said adhesive system comprises at least one polyhydroxy polymer and/or the reaction product of said polyhydroxy polymer with a crosslinking agent, wherein at least one of said support and said foil is transparent; and a security document comprising the above-disclosed laminate or a laminate obtainable by the above-disclosed process.

  一种夹层透明压花全息图的方法，所述透明压花全息图包括一个可选的透明支撑物，该支撑物有两个面，两个面中至少有一个面本身是压花的或其上有一层是压花的，还有一层无机 HRI 材料，该层通过真空技术与所述压花面或压花层相邻，包括以下步骤用至少一种聚羟基聚合物的水溶液或分散液涂覆所述 HRI 材料层的最外表面；干燥所述涂层，从而形成透明的连续可覆膜层 2；以及将所述透明的连续可覆膜层 2 覆膜到可选的透明箔上，其中所述支撑物和所述箔中至少有一个是透明的；一种层压件，包括层间透明压花全息图，所述透明压花全息图包括可选的透明支撑物，支撑物有两个面，两个面中至少有一面本身是压花的，或其上有一层是压花的，以及一层通过真空技术涂覆的 HRI 材料，该层与所述压花面或压花层相邻，在所述 HRI 材料层和可选的透明箔之间有一层粘合剂、其中所述粘合剂系统包括至少一种聚羟基聚合物和/或所述聚羟基聚合物与交联剂的反应产物，其中所述支撑物和所述箔片中至少有一个是透明的；以及一种防伪文件，该文件包括上述层压材料或通过上述工艺获得的层压材料。
• Color developing agent and image forming process
  申请人：FUJI PHOTO FILM CO., LTD.

  公开号：EP0393523B1

  公开（公告）日：1995-12-13
• NOVEL RADIATION CURABLE COMPOSITIONS
  申请人：Loccufier Johan

  公开号：US20100041784A1

  公开（公告）日：2010-02-18

  A radiation curable composition comprising a curable compound, a photo-initiator and a co-initiator characterized in that said co-initiator is represented by Formula (I), wherein MA is the residue of a mono- or oligofunctional Michael acceptor; L is a divalent linking group positioning the two tertiary amines in a 1-3 to 1-10 position, with the proviso that both amines are aliphatic; R1, R2 and R3 independently represent an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group or an optionally substituted (hetero) alkaryl group; any two of R1, R2 and R3 may represent the necessary atoms to form a ring; any two of R1, R2 and R3 may represent the necessary atoms to form a ring with any of the atoms of the linking group L; n is an integer ranging from 1 to 6.